A5086034320- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Epilepsy research and treatment
- Bipolar Disorder and Treatment
- Ubiquitin and proteasome pathways
- Hematological disorders and diagnostics
- Immune cells in cancer
- Chronic Myeloid Leukemia Treatments
- Synthesis and Biological Evaluation
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Retinoids in leukemia and cellular processes
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
- Microtubule and mitosis dynamics
Bristol-Myers Squibb (United States)
2022-2024
University of Washington
2014-2022
Fred Hutch Cancer Center
2018-2022
Seattle Cancer Care Alliance
2020
Seattle University
2017-2019
University of Washington Medical Center
2019
Translational Research in Oncology
2018
Hutchison/MRC Research Centre
2009
Medical Research Council
2009
University of Cambridge
2009
Five rapid-cycling manic patients developed neurotoxic syndromes when treated with a combination of lithium and carbamazepine, although all five had therapeutic plasma levels both drugs. The risk factors for development neurotoxicity this drug are discussed.
With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an Italian panel of experts are widely used this purpose. How these Ferrara predict fitness chemotherapy unknown.We assessed the adults undergoing AML therapy based on and determined accuracy assessment early mortality survival prediction.Among 655 who received...
Whether the number of chemotherapy cycles required to obtain a first morphological remission affects prognosis patients with acute myeloid leukemia (AML) remains controversial. To clarify how achievement early might influence outcome allogeneic hematopoietic cell transplantation (HCT), we studied 220 consecutive adults AML in who underwent after myeloablative or nonmyeloablative conditioning investigate standard- high-dose induction courses achieve impacted post-HCT outcome. Three-year...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: ALNUC, a 2 + 1 T-cell engager (TCE) with bivalent binding to BCMA, has demonstrated clinical activity in pts RRMM an open-label phase study (NCT03486067). IV-administered ALNUC exhibited long duration of response (DOR) but resulted cytokine release syndrome (CRS) 76% treated pts. Subcutaneous (SC) dosing reduced CRS rate severity, allowing escalation higher target doses, while showing promising antitumor activity....
Alnuctamab, a B-cell maturation antigen (BCMA)-targeting T-cell engager, has demonstrated encouraging antitumor activity in the phase I study CC-93269-MM-001 treating patients with relapsed or refractory multiple myeloma. Identification of recommended Phase III dose (RP3D) was key objective, as such population pharmacokinetic (PopPK) and exposure-response analysis critical. Intravenous (IV) alnuctamab administered fixed doses (0.15-10 mg) step-up to maximum 10-mg target dose. Subcutaneous...
Dexamethasone suppression tests (DSTs) were given to nine bipolar patients in both depressed and manic phases of their illness. In seven DST results consistent between episodes; six had positive depression mania.
Gemtuzumab ozogamicin (GO) improves outcomes when added to intensive AML chemotherapy. A meta-analysis suggested the greatest benefit combining fractionated doses of GO (GO3) with 7 + 3. To test whether GO3 can be safely used high intensity chemotherapy, we conducted a phase 1/2 study cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone (CLAG-M) in adults newly diagnosed or other high-grade myeloid neoplasm (NCT03531918). Sixty-six patients median age 65 (range: 19-80)...
Eighteen manic patients who had abnormal results on the dexamethasone suppression test at admission were retested before discharge, when they clinically stable. Conversion to normal predicted good outcome after whereas a persistently poor outcome.